Which has higher earnings and valuation, VTRS or LNTH?

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.30 -$3.51B -$0.36 N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.38

Is VTRS or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Viatris' net margin of -2.79%. Lantheus' return on equity of 28.10% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Lantheus 17.69% 28.10% 14.35%

Does the media refer more to LNTH or JAZZ?

In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 10 mentions for Lantheus. Lantheus' average media sentiment score of 1.06 beat Jazz Pharmaceuticals' score of 0.56 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NBIX or LNTH?

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Neurocrine Biosciences and 10 mentions for Lantheus. Lantheus' average media sentiment score of 1.06 beat Neurocrine Biosciences' score of 0.67 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, LNTH or CORT?

Lantheus has higher revenue and earnings than Corcept Therapeutics. Lantheus is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.14 24.38 Corcept Therapeutics $761.41M 16.25 $99.65M $0.42 272.55

Does the media refer more to LNTH or CORT?

In the previous week, Lantheus had 2 more articles in the media than Corcept Therapeutics. MarketBeat recorded 10 mentions for Lantheus and 8 mentions for Corcept Therapeutics. Lantheus' average media sentiment score of 1.06 beat Corcept Therapeutics' score of 1.03 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or LNTH?

In the previous week, Elanco Animal Health had 11 more articles in the media than Lantheus. MarketBeat recorded 21 mentions for Elanco Animal Health and 10 mentions for Lantheus. Lantheus' average media sentiment score of 1.06 beat Elanco Animal Health's score of 0.83 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 8 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lantheus (LNTH) Competitors

$100.95 +0.01 (+0.01%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$99.60 -1.35 (-1.34%)

As of 08/14/2026 07:34 PM Eastern

Compare

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Lantheus stock or one of its competitors? Lantheus's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lantheus compare to Viatris?

Viatris (NASDAQ:VTRS) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.30	-$3.51B	-$0.36	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.38

Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 7.83%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.09%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Viatris is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

79.9% of Viatris shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Lantheus had 9 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Lantheus and 1 mentions for Viatris. Viatris' average media sentiment score of 1.89 beat Lantheus' score of 1.06 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Very Positive
Lantheus	Positive

Lantheus has a net margin of 17.69% compared to Viatris' net margin of -2.79%. Lantheus' return on equity of 28.10% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Lantheus	17.69%	28.10%	14.35%

Summary

Lantheus beats Viatris on 11 of the 16 factors compared between the two stocks.

How does Lantheus compare to Jazz Pharmaceuticals?

Lantheus (NASDAQ:LNTH) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Lantheus has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.38
Jazz Pharmaceuticals	$4.60B	3.46	-$356.15M	$14.50	16.89

In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 10 mentions for Lantheus. Lantheus' average media sentiment score of 1.06 beat Jazz Pharmaceuticals' score of 0.56 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus target price of $108.11, indicating a potential upside of 7.09%. Jazz Pharmaceuticals has a consensus target price of $272.89, indicating a potential upside of 11.40%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

99.1% of Lantheus shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Lantheus' net margin of 17.69%. Jazz Pharmaceuticals' return on equity of 33.97% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Summary

Jazz Pharmaceuticals beats Lantheus on 11 of the 17 factors compared between the two stocks.

How does Lantheus compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Neurocrine Biosciences and 10 mentions for Lantheus. Lantheus' average media sentiment score of 1.06 beat Neurocrine Biosciences' score of 0.67 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Lantheus. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.60	$478.60M	$6.82	22.39
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.38

Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 20.91% compared to Lantheus' net margin of 17.69%. Lantheus' return on equity of 28.10% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Lantheus	17.69%	28.10%	14.35%

Neurocrine Biosciences presently has a consensus price target of $200.86, suggesting a potential upside of 31.52%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.09%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Neurocrine Biosciences beats Lantheus on 13 of the 17 factors compared between the two stocks.

How does Lantheus compare to Corcept Therapeutics?

Lantheus (NASDAQ:LNTH) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Lantheus had 2 more articles in the media than Corcept Therapeutics. MarketBeat recorded 10 mentions for Lantheus and 8 mentions for Corcept Therapeutics. Lantheus' average media sentiment score of 1.06 beat Corcept Therapeutics' score of 1.03 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Corcept Therapeutics' net margin of 6.52%. Lantheus' return on equity of 28.10% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Corcept Therapeutics	6.52%	8.26%	6.45%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus currently has a consensus price target of $108.11, indicating a potential upside of 7.09%. Corcept Therapeutics has a consensus price target of $119.17, indicating a potential upside of 4.10%. Given Lantheus' higher probable upside, research analysts clearly believe Lantheus is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Lantheus has higher revenue and earnings than Corcept Therapeutics. Lantheus is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.38
Corcept Therapeutics	$761.41M	16.25	$99.65M	$0.42	272.55

Summary

Lantheus beats Corcept Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Lantheus compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Elanco Animal Health currently has a consensus target price of $29.09, indicating a potential upside of 23.07%. Lantheus has a consensus target price of $108.11, indicating a potential upside of 7.09%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Elanco Animal Health is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Elanco Animal Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

In the previous week, Elanco Animal Health had 11 more articles in the media than Lantheus. MarketBeat recorded 21 mentions for Elanco Animal Health and 10 mentions for Lantheus. Lantheus' average media sentiment score of 1.06 beat Elanco Animal Health's score of 0.83 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to Elanco Animal Health's net margin of -3.96%. Lantheus' return on equity of 28.10% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Lantheus	17.69%	28.10%	14.35%

Lantheus has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.50	-$232M	-$0.41	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.38

Summary

Lantheus beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.59B	$11.80B	$7.03B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.65%
P/E Ratio	24.38	779.99	271.26	25.38
Price / Sales	4.27	748.85	623.44	105.58
Price / Cash	15.81	89.04	75.70	53.27
Price / Book	5.02	11.60	12.92	6.21
Net Income	$233.56M	$2.77B	$3.45B	$347.71M
7 Day Performance	N/A	0.14%	1.16%	1.08%
1 Month Performance	-3.96%	0.65%	2.17%	1.87%
1 Year Performance	86.32%	145.68%	62.38%	20.79%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	3.3038 of 5 stars	$100.95 +0.0%	$108.11 +7.1%	+86.3%	$6.59B	$1.54B	24.38	1,193	Positive News
VTRS Viatris	2.5247 of 5 stars	$16.28 -0.9%	$17.50 +7.5%	+53.0%	$19.13B	$14.30B	N/A	30,000	Positive News
JAZZ Jazz Pharmaceuticals	4.1037 of 5 stars	$256.52 0.0%	$272.74 +6.3%	+108.0%	$16.65B	$4.27B	17.69	2,890	Analyst Forecast
NBIX Neurocrine Biosciences	4.987 of 5 stars	$164.92 +0.9%	$201.50 +22.2%	+14.9%	$16.61B	$2.86B	24.18	2,000	Analyst Downgrade
CORT Corcept Therapeutics	2.735 of 5 stars	$114.23 +3.1%	$119.17 +4.3%	+59.5%	$11.97B	$830.81M	271.98	300	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Lantheus compare to Viatris?

Summary

How does Lantheus compare to Jazz Pharmaceuticals?

Summary

How does Lantheus compare to Neurocrine Biosciences?

Summary

How does Lantheus compare to Corcept Therapeutics?

Summary

How does Lantheus compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH vs. The Competition

Lantheus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantheus (LNTH) Competitors

LNTH vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Lantheus compare to Viatris?

Which has higher earnings and valuation, VTRS or LNTH?

Which has more risk and volatility, VTRS or LNTH?

Do analysts rate VTRS or LNTH?

Do institutionals & insiders hold more shares of VTRS or LNTH?

Does the media prefer VTRS or LNTH?

Is VTRS or LNTH more profitable?

Summary

How does Lantheus compare to Jazz Pharmaceuticals?

Which has more risk & volatility, LNTH or JAZZ?

Which has higher valuation & earnings, LNTH or JAZZ?

Does the media refer more to LNTH or JAZZ?

Do analysts rate LNTH or JAZZ?

Do insiders and institutionals believe in LNTH or JAZZ?

Is LNTH or JAZZ more profitable?

Summary

How does Lantheus compare to Neurocrine Biosciences?

Do institutionals & insiders hold more shares of NBIX or LNTH?

Does the media favor NBIX or LNTH?

Which has preferable earnings and valuation, NBIX or LNTH?

Which has more volatility and risk, NBIX or LNTH?

Is NBIX or LNTH more profitable?

Do analysts prefer NBIX or LNTH?

Summary

How does Lantheus compare to Corcept Therapeutics?

Does the media refer more to LNTH or CORT?

Which has more risk and volatility, LNTH or CORT?

Is LNTH or CORT more profitable?

Do insiders & institutionals have more ownership in LNTH or CORT?

Do analysts recommend LNTH or CORT?

Which has preferable earnings and valuation, LNTH or CORT?

Summary

How does Lantheus compare to Elanco Animal Health?

Do analysts prefer ELAN or LNTH?

Which has more volatility and risk, ELAN or LNTH?

Does the media favor ELAN or LNTH?

Do insiders and institutionals believe in ELAN or LNTH?

Is ELAN or LNTH more profitable?

Which has preferable valuation and earnings, ELAN or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH vs. The Competition

Lantheus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools